This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

ICU Medical, Inc.
11/5/2026
Good afternoon, everyone, and welcome to today's ICO Medical, Inc. 3rd Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question at that time, please press star 1. Also, please note that today's event is being recorded. I'd now like to turn the conference over to Deirdre Thompson, ICR Senior Vice President. Please go ahead.
Thank you for joining us to discuss ICU Medical's financial results for the third quarter of 2026. On the call today representing ICU Medical is Vivek Jain, Chief Executive Officer and Chairman, and Brian Bonnell, Chief Financial Officer. We wanted to let everyone know that we have a presentation accompanying today's prepared remarks. To view the presentation, please go to our investor page and click on events calendar, and it will be under third quarter 2026 events. Before we start our prepared remarks, we want to touch upon any forward-looking statements made during the call, including beliefs and expectations about the company's future results. Please be aware they are based on the best available information to management and assumptions that are reasonable. Such statements are not intended to be a representation of future results and are subject to risk and uncertainty. Future results may differ materially from management's current expectations. We refer all of you to the company's FCC filings for more detailed information on the risks and uncertainties that have a direct bearing on operating results and financial position. Please note that during today's call, we will also discuss non-GAAP financial measures, including results on an adjusted basis. We believe these financial measures can facilitate a more complete analysis and greater transparency into IT medical's ongoing results of operations, particularly when comparing underlying results from period to period We've also included a reconciliation of these non-GAAP measures in today's release and provide as much detail as possible on any addendums that are added back. And with that, it is my pleasure to turn the call over to Vivek.
Thanks, Deirdre, and good afternoon, everyone. I'll walk through our Q3 revenue and earnings performance and provide some color on the businesses, and then turn it over to Brian who will recap the full Q3 results. After that, I'll come back with a few updates on product development initiatives, and some comments on our performance against our near and midterm financial goals and our latest capital allocation strategy. Revenue for Q3 was $556 million for total company growth of 5% on an organic basis or 4% reported as the reported results are no longer impacted by the mid-2025 creation of the Apsuka ICU Medical joint venture and the resulting deconsolidation of IV solutions from our income statement. Adjusted gross margins were strong at just over 42%, adjusted EBITDA improved to $114 million, and adjusted EPS was $2.44. Organic free cash flow was again healthy, and when combined with tariff refunds, which are excluded from our P&L commentary today, we're able to repay approximately $80 million of debt in the quarter, and we'll finish 2026 slightly below two times net leverage. The broader demand and utilization environment in Q3 continued to be stable with volume in line with our guidance assumptions for the year. The capital environment is status quo and it does appear investments that customers need to get done do get done. The only change in currency since the last call is the strengthening dollar against the euro. During Q3, we did move forward consolidating the legacy Smith's physical distribution and logistics into a common network. We did have some operational bumps which were more impactful in the international markets. As a result, North America drove the growth in Q3 due to this issue as well as the previously mentioned OEM wind down is recognized in the international geographies. In terms of minimizing any impact from the logistics consolidation, we prioritized infusion systems products first, infusion consumables second, and vital care products third. So the business results I'm going to describe momentarily reflect this hierarchy. In aggregate, there was no net impact to the revenue expectations for the company, but the overall mix was slightly impacted. Getting to our businesses more specifically, our consumables business grew 5% in Q3 reported and was a record in absolute sales. We did have both good sequential growth and annual growth as the step up last year between Q2 and Q3 was substantial. Growth was driven more by the legacy ICU product lines of infusion therapy and oncology due to healthy census, share gains, and the hierarchy mentioned above. We continue to believe the business will deliver mid-single-digit growth for 2026 and likely follow the same trends as previous years. Our IV systems business grew 11%, both reported and organic in Q3, and it was again a record quarter for the business. Dedicated sets generally follow the same trend as consumables and capital sales. We're strong through the quarter, offset by declines in the OEM revenues. For Q4, we do feel some volume that we had scheduled for early 2027 is coming in earlier than planned. And as a result, we think this business will be at least high single digits for the full year of 2026. Just wrapping up the businesses, in Q3, vital care decreased 10% on an organic basis. and decreased 12% reported due largely to the logistics consolidation described above. We expect sequential improvements here, as we should have most of the challenges solved in Q4, but with the impact of the Q3 results, this business will have a larger year-over-year decrease than previously mentioned. There's nothing deeper here. We just have some cleanup of the integrations, which is happening as we speak, and it's basic blocking and tackling. With that, I'll turn it over to Brian and then come back with some commentary to assess our financial performance and how it aligns with our strategic goals. Brian, over to you.
You're reading a preview of the ICUI Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing